Fintel reports that on January 29, 2025, Truist Securities initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a Buy recommendation.
Analyst Price Forecast Suggests 491.11% Upside
As of January 29, 2025, the average one-year price target for Larimar Therapeutics is $21.93/share. The forecasts range from a low of $14.14 to a high of $37.80. The average price target represents an increase of 491.11% from its latest reported closing price of $3.71 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Larimar Therapeutics is 0MM. The projected annual non-GAAP EPS is -2.00.
What is the Fund Sentiment?
There are 253 funds or institutions reporting positions in Larimar Therapeutics. This is an increase of 18 owner(s) or 7.66% in the last quarter. Average portfolio weight of all funds dedicated to LRMR is 0.08%, an increase of 29.77%. Total shares owned by institutions increased in the last three months by 1.35% to 68,031K shares. 
The put/call ratio of LRMR is 0.08, indicating a bullish outlook.
What are Other Shareholders Doing?
Deerfield Management Company, L.p. holds 21,232K shares representing 33.28% ownership of the company. No change in the last quarter.
Ra Capital Management holds 6,045K shares representing 9.47% ownership of the company. No change in the last quarter.
Janus Henderson Group holds 5,567K shares representing 8.72% ownership of the company. In its prior filing, the firm reported owning 4,377K shares , representing an increase of 21.37%. The firm increased its portfolio allocation in LRMR by 9.94% over the last quarter.
Goldman Sachs Group holds 4,249K shares representing 6.66% ownership of the company. In its prior filing, the firm reported owning 4,333K shares , representing a decrease of 1.96%. The firm decreased its portfolio allocation in LRMR by 15.63% over the last quarter.
Blue Owl Capital Holdings holds 4,167K shares representing 6.53% ownership of the company. In its prior filing, the firm reported owning 3,859K shares , representing an increase of 7.38%. The firm decreased its portfolio allocation in LRMR by 32.70% over the last quarter.
Larimar Therapeutics Background Information
(This description is provided by the company.)
Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for FA. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
